Overall, the authors believe that this research demonstrates potential for concomitant TTFields and sorafenib application in the treatment of HCC.
While I do not know if the authors have the technology to perform TTFields in mice, where for sure they should have done xenograft models with the two human cell lines, why the rat cell line was not studied in vitro using the same experimental strategies as for human cells.